Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, Pavia (PV) 27100, Italy.
Eur Heart J. 2009 Aug;30(16):2003-10. doi: 10.1093/eurheartj/ehp152. Epub 2009 May 27.
To assess the relationship between cardiovascular magnetic resonance (CMR) parameters and both spontaneous ventricular tachycardia (VT) and risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) patients.
One hundred and eight consecutive HCM patients (mean age 42 +/- 15 years, 76% males) underwent CMR evaluation and risk assessment. Delayed contrast enhancement (DCE) was quantified with a specifically designed score. Endpoints were either the presence of clinical VT/ventricular fibrillation (VF) or of acknowledged risk factors for SCD. Compared to patients without arrhythmia, those with VT/VF (n = 33) had a higher DCE score [median 8 (2-13) vs. 11 (6-20); P = 0.01]; DCE score was also the only independent predictor of VT/VF in the multivariable model. DCE score [median 6 (1-10.5) vs. 12 (6-18); P = 0.001], mean and maximal left ventricular (LV) wall thickness (MaxLVWT), as well as LV mass index were significantly greater among patients at risk for SCD (n = 51) compared with the remaining 57 patients at low risk. DCE score and MaxLVWT were independent predictors of SCD risk.
In HCM patients several CMR parameters are associated with risk for SCD. A semi-quantitative index of DCE is a significant multivariable predictor of both clinical VT/VF and of risk for SCD and may contribute to risk assessment in borderline or controversial cases.
评估心血管磁共振(CMR)参数与肥厚型心肌病(HCM)患者自发性室性心动过速(VT)和心源性猝死(SCD)风险的关系。
108 例连续 HCM 患者(平均年龄 42±15 岁,76%为男性)接受 CMR 评估和风险评估。通过专门设计的评分来量化延迟对比增强(DCE)。终点为临床 VT/室颤(VF)的存在或公认的 SCD 危险因素。与无心律失常患者相比,VT/VF 患者(n=33)的 DCE 评分更高[中位数 8(2-13)比 11(6-20);P=0.01];DCE 评分也是多变量模型中 VT/VF 的唯一独立预测因子。DCE 评分[中位数 6(1-10.5)比 12(6-18);P=0.001]、平均和最大左心室(LV)壁厚度(MaxLVWT)以及 LV 质量指数在 SCD 风险患者(n=51)中明显高于低风险患者(n=57)。DCE 评分和 MaxLVWT 是 SCD 风险的独立预测因子。
在 HCM 患者中,几种 CMR 参数与 SCD 风险相关。DCE 的半定量指数是临床 VT/VF 和 SCD 风险的重要多变量预测因子,可能有助于边界或有争议病例的风险评估。